WO2007141657A3 - Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation - Google Patents

Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation Download PDF

Info

Publication number
WO2007141657A3
WO2007141657A3 PCT/IB2007/002292 IB2007002292W WO2007141657A3 WO 2007141657 A3 WO2007141657 A3 WO 2007141657A3 IB 2007002292 W IB2007002292 W IB 2007002292W WO 2007141657 A3 WO2007141657 A3 WO 2007141657A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
factor
derivatives
cells
human embryonic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/002292
Other languages
French (fr)
Other versions
WO2007141657B1 (en
WO2007141657A2 (en
Inventor
Geeta Shroff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK07789615.7T priority Critical patent/DK1993575T3/en
Priority to JP2008557853A priority patent/JP5649786B2/en
Priority to ES07789615T priority patent/ES2748475T3/en
Priority to BRPI0708576-1A priority patent/BRPI0708576A2/en
Priority to AU2007257594A priority patent/AU2007257594B2/en
Priority to US12/224,839 priority patent/US10545135B2/en
Priority to KR1020087024426A priority patent/KR101505202B1/en
Priority to NZ571127A priority patent/NZ571127A/en
Priority to EA200801943A priority patent/EA027648B9/en
Application filed by Individual filed Critical Individual
Priority to MX2008011279A priority patent/MX347303B/en
Priority to KR1020147030666A priority patent/KR101505382B1/en
Priority to CNA200780013128XA priority patent/CN101420964A/en
Priority to EP07789615.7A priority patent/EP1993575B1/en
Priority to CA2644922A priority patent/CA2644922C/en
Priority to AP2008004623A priority patent/AP2949A/en
Publication of WO2007141657A2 publication Critical patent/WO2007141657A2/en
Publication of WO2007141657A3 publication Critical patent/WO2007141657A3/en
Publication of WO2007141657B1 publication Critical patent/WO2007141657B1/en
Priority to IL193702A priority patent/IL193702A/en
Priority to CU2008000161A priority patent/CU20080161A7/en
Anticipated expiration legal-status Critical
Priority to NO20084181A priority patent/NO20084181L/en
Priority to US13/735,281 priority patent/US8592208B2/en
Priority to US13/735,294 priority patent/US9383349B2/en
Priority to CU2013000075A priority patent/CU20130075A7/en
Priority to US14/061,420 priority patent/US8900861B2/en
Priority to US14/062,512 priority patent/US9482660B2/en
Priority to US14/063,573 priority patent/US9804151B2/en
Priority to US14/063,606 priority patent/US9488643B2/en
Priority to US14/068,252 priority patent/US9134299B2/en
Priority to PH12014501028A priority patent/PH12014501028A1/en
Priority to US16/204,601 priority patent/US20190369088A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/31—Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising of preparations of human embryonic stem (hES) cells and their derivatives and methods for their transplantation into the human body, wherein transplantation results in the clinical reversal of symptoms, cure, stabilization or arrest of degeneration of a wide variety of presently incurable and terminal medical conditions, diseases and disorders. The invention further relates to novel processes of preparing novel stem cell lines which are free of animal products, feeder cells, growth factors, leukaemia inhibitory factor, supplementary mineral combinations, amino acid supplements, vitamin supplements, fibroblast growth factor, membrane associated steel factor, soluble steel factor and conditioned media. This invention further relates to the isolation, culture, maintenance, expansion, differentiation, storage, and preservation of such stem cells.
PCT/IB2007/002292 2006-03-07 2007-03-06 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation Ceased WO2007141657A2 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
EA200801943A EA027648B9 (en) 2006-03-07 2007-03-06 COMPOSITIONS COMPRISING HUMAN EMBRYONIC STEM CELLS (hES) OR Hes DERIVATIVE CELLS, AND USE THEREOF
ES07789615T ES2748475T3 (en) 2006-03-07 2007-03-06 Compositions comprising human embryonic stem cells and their derivatives, methods of use and preparation procedures
MX2008011279A MX347303B (en) 2006-03-07 2007-03-06 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation.
AU2007257594A AU2007257594B2 (en) 2006-03-07 2007-03-06 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
US12/224,839 US10545135B2 (en) 2006-03-07 2007-03-06 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
KR1020087024426A KR101505202B1 (en) 2006-03-07 2007-03-06 Composition comprising human embryonic stem cells and derivatives thereof, method of use thereof and method of manufacture
NZ571127A NZ571127A (en) 2006-03-07 2007-03-06 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
DK07789615.7T DK1993575T3 (en) 2006-03-07 2007-03-06 COMPOSITIONS INCLUDING HUMAN EMBYO STAM CELLS AND DERIVATIVES THEREOF, METHODS OF USE AND PROCEDURES FOR MANUFACTURING
BRPI0708576-1A BRPI0708576A2 (en) 2006-03-07 2007-03-06 composition comprising human embryonic stem cells and their derivatives, methods of use and methods of preparation
JP2008557853A JP5649786B2 (en) 2006-03-07 2007-03-06 Compositions containing human embryonic stem cells and their derivatives, methods of use, and methods of preparation
KR1020147030666A KR101505382B1 (en) 2006-03-07 2007-03-06 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
CNA200780013128XA CN101420964A (en) 2006-03-07 2007-03-06 Compositions comprising human embryonic stem cells and derivatives thereof, methods of use and methods of preparation thereof
EP07789615.7A EP1993575B1 (en) 2006-03-07 2007-03-06 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
CA2644922A CA2644922C (en) 2006-03-07 2007-03-06 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
AP2008004623A AP2949A (en) 2006-03-07 2007-03-06 Compositions comprising human embryonic stem cellsand their derivatives, methods of use, and method s of preparation
IL193702A IL193702A (en) 2006-03-07 2008-08-26 Pharmaceutical composition containing human embryonic stem cells, methods of producing same and uses thereof
CU2008000161A CU20080161A7 (en) 2006-03-07 2008-09-05 COMPOSITIONS THAT INCLUDE MOTHER CELLS OF SELECTED FABRICS AND PREPARATION METHODS
NO20084181A NO20084181L (en) 2006-03-07 2008-10-06 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
US13/735,281 US8592208B2 (en) 2006-03-07 2013-01-07 Methods of expanding human embryonic stem cells
US13/735,294 US9383349B2 (en) 2006-03-07 2013-01-07 Method of partially differentiating hES cells
CU2013000075A CU20130075A7 (en) 2006-09-14 2013-05-30 PHARMACEUTICAL COMPOSITION THAT INCLUDES HUMAN MOTHER CELLS AND THEIR DERIVATIVES AND PREPARATION METHODS
US14/061,420 US8900861B2 (en) 2006-03-07 2013-10-23 Method for storing a preparation of human embryonic stem cells
US14/062,512 US9482660B2 (en) 2006-03-07 2013-10-24 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
US14/063,606 US9488643B2 (en) 2006-03-07 2013-10-25 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
US14/063,573 US9804151B2 (en) 2006-03-07 2013-10-25 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
US14/068,252 US9134299B2 (en) 2006-03-07 2013-10-31 Method of isolating human embryonic stem cells in minimal essential medium
PH12014501028A PH12014501028A1 (en) 2006-03-07 2014-05-06 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
US16/204,601 US20190369088A1 (en) 2006-03-07 2018-11-29 Compositions Comprising Human Embryonic Stem Cells and Their Derivatives, Methods of Use, and Methods of Preparation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN582DE2006 2006-03-07
IN582/DEL/2006 2006-03-07
IN1500/DEL/2006 2006-06-26
IN1500DE2006 2006-06-26
US84435006P 2006-09-14 2006-09-14
US60/844,350 2006-09-14

Related Child Applications (9)

Application Number Title Priority Date Filing Date
US12/224,839 A-371-Of-International US10545135B2 (en) 2006-03-07 2007-03-06 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
US13/735,294 Division US9383349B2 (en) 2006-03-07 2013-01-07 Method of partially differentiating hES cells
US13/735,281 Division US8592208B2 (en) 2006-03-07 2013-01-07 Methods of expanding human embryonic stem cells
US14/061,420 Division US8900861B2 (en) 2006-03-07 2013-10-23 Method for storing a preparation of human embryonic stem cells
US14/062,512 Division US9482660B2 (en) 2006-03-07 2013-10-24 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
US14/063,573 Division US9804151B2 (en) 2006-03-07 2013-10-25 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
US14/063,606 Division US9488643B2 (en) 2006-03-07 2013-10-25 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
US14/068,252 Division US9134299B2 (en) 2006-03-07 2013-10-31 Method of isolating human embryonic stem cells in minimal essential medium
US16/204,601 Continuation US20190369088A1 (en) 2006-03-07 2018-11-29 Compositions Comprising Human Embryonic Stem Cells and Their Derivatives, Methods of Use, and Methods of Preparation

Publications (3)

Publication Number Publication Date
WO2007141657A2 WO2007141657A2 (en) 2007-12-13
WO2007141657A3 true WO2007141657A3 (en) 2008-04-24
WO2007141657B1 WO2007141657B1 (en) 2008-07-31

Family

ID=54150153

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/002292 Ceased WO2007141657A2 (en) 2006-03-07 2007-03-06 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation

Country Status (23)

Country Link
US (9) US10545135B2 (en)
EP (11) EP2422801A3 (en)
JP (2) JP5649786B2 (en)
KR (2) KR101505382B1 (en)
CN (2) CN101420964A (en)
AP (1) AP2949A (en)
AU (1) AU2007257594B2 (en)
BR (1) BRPI0708576A2 (en)
CA (1) CA2644922C (en)
CR (1) CR10345A (en)
CU (1) CU20080161A7 (en)
DK (1) DK1993575T3 (en)
EA (1) EA027648B9 (en)
EC (1) ECSP088799A (en)
GE (1) GEP20135796B (en)
IL (1) IL193702A (en)
MA (1) MA30323B1 (en)
MX (1) MX347303B (en)
MY (1) MY154677A (en)
NO (1) NO20084181L (en)
NZ (2) NZ571127A (en)
PH (1) PH12014501028A1 (en)
WO (1) WO2007141657A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102119031B (en) * 2008-06-11 2014-09-10 弗雷森纽斯医疗护理德国有限责任公司 Conditioned media for hepatic progenitor cells

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20135796B (en) 2006-03-07 2013-04-10 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
CN101668848B (en) 2007-04-26 2014-10-22 雷蒙特亚特特拉维夫大学有限公司 Pluripotent autologous stem cells from oral mucosa and methods of use
EP2164505B1 (en) * 2007-05-28 2014-09-17 Monash University Treatment of chronic lung disease
US20090291061A1 (en) * 2008-05-21 2009-11-26 Riordan Neil H Stem cell therapy for blood vessel degeneration
RU2364382C1 (en) * 2008-05-29 2009-08-20 Федеральное государственное учреждение "МОСКОВСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ ИМЕНИ ГЕЛЬМГОЛЬЦА ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ВЫСОКОТЕХНОЛОГИЧНОЙ МЕДИЦИНСКОЙ ПОМОЩИ" Method of increment in retina capacity with various pathologies
WO2010006261A1 (en) * 2008-07-10 2010-01-14 Hong John J Methods for inducing stem cell migration and specialization with ec-18
RU2385746C1 (en) * 2008-07-18 2010-04-10 Владимир Алексеевич Шатров Method of treating infantile cerebral paralysis
EP2356227B1 (en) * 2008-11-14 2018-03-28 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
GB201111244D0 (en) * 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
RU2428956C2 (en) * 2009-07-13 2011-09-20 Александр Дмитриевич Ромащенко Method of treating optic nerve by transplantation of autologic stem cells
US8377432B2 (en) * 2009-09-02 2013-02-19 Khay-Yong Saw Method and composition for neochondrogenesis
CA2772619C (en) * 2009-09-04 2019-07-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for enhancing genome stability and telomere elongation in embryonic stem cells
WO2011047345A2 (en) * 2009-10-15 2011-04-21 Tai June Yoo Methods of treating diseases of conditions using mesenchymal stem cells
WO2011070974A1 (en) * 2009-12-07 2011-06-16 国立大学法人名古屋大学 Cell preparation for treating prostatic cancer comprising adipose tissue-derived mesenchymal stem cells
KR20130092394A (en) * 2010-04-08 2013-08-20 안트로제네시스 코포레이션 Treatment of sarcoidosis using placental stem cells
WO2011145110A1 (en) 2010-05-15 2011-11-24 Subhadra Dravida A novel cord blood plasma nutrient formulation and a method for the preparation thereof
US9724367B2 (en) * 2010-11-10 2017-08-08 Regenmed (Cayman) Ltd. Injectable formulations for organ augmentation
FR2986537B1 (en) * 2012-02-07 2014-03-28 Oreal METHOD OF EVALUATING ASSAY (S) APT (S) TO PRESERVE THE FUNCTIONALITY OF EPITHELIAL STEM CELLS
WO2013158258A1 (en) * 2012-04-16 2013-10-24 The Regents Of The University Of California Ocular therapeutics using embryonic system cell microvesicles
WO2014089121A2 (en) * 2012-12-03 2014-06-12 Thomas Ichim Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US20150335714A1 (en) * 2013-01-25 2015-11-26 Tammy Z. Movsas Use of human chorionic gonadotropin to inhibit development or minimize severity of cerebral palsy and/or its co-morbidities
CN103961373A (en) 2013-02-04 2014-08-06 西比曼生物科技（上海）有限公司 Application of allogenic interstitial vascular cell and allogenic mesenchymal progenitor cell in prevention or treatment of rheumatoid arthritis
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
ITMI20130513A1 (en) * 2013-04-05 2014-10-06 Euroclone S P A DIAGNOSTIC METHOD FOR AUTOIMMUNE PATHOLOGIES OF THE LIVER
WO2015173425A1 (en) 2014-05-16 2015-11-19 Koninklijke Nederlandse Akademie Van Wetenschappen Improved culture method for organoids
KR101686315B1 (en) 2015-01-09 2016-12-13 이화여자대학교 산학협력단 A method for differentiation of tonsil-derived mesenchymal stem cell into schwann cells
KR20160109358A (en) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 A composition for preventing or treating of immune disease
KR102036029B1 (en) 2015-03-11 2019-10-24 이화여자대학교 산학협력단 A composition for preventing or treating of bone marrow failure
KR20160109356A (en) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 A composition for preventing or treating of auto-immune disease
US10870830B2 (en) 2015-03-26 2020-12-22 EWHA University—Industry Collaboration Foundation Method for culturing differentiation-promoting and -sustaining spheroid form of tonsil-derived stem cells
WO2016196661A1 (en) 2015-06-01 2016-12-08 Memorial Sloan-Kettering Cancer Center Methods of in vitro differentiation of midbrain dopamine (mda) neurons
WO2017112901A1 (en) 2015-12-23 2017-06-29 Memorial Sloan-Kettering Cancer Center Cell-based treatment and drug discovery in hirschsprung's disease enabled by pluripotent stem cell-derived human enteric neural crest lineages
JP7523885B2 (en) 2016-02-05 2024-07-29 メモリアル スローン ケタリング キャンサー センター Methods for differentiating stem cell-derived ectodermal lineage precursors - Patents.com
CN105749254A (en) * 2016-02-28 2016-07-13 深圳爱生再生医学科技有限公司 Stem cell preparation used for treating vascular dementia as well as preparation method and application thereof
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
WO2017205746A1 (en) 2016-05-27 2017-11-30 Memorial Sloan-Kettering Cancer Center Methods of differentiating stem cell-derived proprioceptors
US12161111B2 (en) * 2016-09-23 2024-12-10 Peter Friedman Compositions and methods for treating citrus plants infected with bacteria and for promoting general agricultural health
CN106177918A (en) * 2016-09-30 2016-12-07 广州赛莱拉干细胞科技股份有限公司 A kind of mesenchymal stem cell injection and its preparation method and application
AU2018215170B2 (en) * 2017-01-31 2021-11-11 Osaka University Differentiation control method for pluripotent stem cells
WO2019040790A1 (en) 2017-08-23 2019-02-28 Merakris Therapeutics, Llc Compositions containing amniotic components and methods for preparation and use thereof
CN111356447B (en) 2017-11-16 2023-03-24 艾维塔生物医学公司 Use of cell membrane-bound signaling factors
GB201721615D0 (en) 2017-12-21 2018-02-07 Koninklijke Nederlandse Akademie Van Wetenschappen Immune cell organoid co-cultures
KR102130493B1 (en) 2018-07-11 2020-07-06 이화여자대학교 산학협력단 A composition for preventing or treating of psoriasis
KR102089476B1 (en) 2018-07-11 2020-03-16 이화여자대학교 산학협력단 A composition for preventing or treating of skin inflammation disease
GB201819224D0 (en) 2018-11-26 2019-01-09 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatocyte expansion methods
AU2020228303B2 (en) 2019-02-28 2025-09-18 Merakris Therapeutics Llc Amniotic fluid-derived extracellular vesicles and uses thereof for wound healing
KR20190120141A (en) 2019-10-16 2019-10-23 이화여자대학교 산학협력단 A composition for preventing or treating of bone marrow failure
KR20210119766A (en) * 2020-03-25 2021-10-06 서울대학교병원 Pharmaceutical composition for preventing or treating retinitis pigmentosa comprising human embryonic stem cell-derived mesenchymal stem cell
EP4171592A4 (en) 2020-06-26 2024-07-31 Minerva Biotechnologies Corporation METHODS OF DERIVING DOPAMINERGIC NEURONS FROM PLURIPOTENT STEM CELLS
US12129483B2 (en) 2020-12-18 2024-10-29 University Of Georgia Research Foundation, Inc. Compositions and methods for making sensory neurons
CN117500916A (en) 2021-04-16 2024-02-02 博恩赛尔公司 Methods for preparing, expanding and purifying midbrain dopaminergic progenitor cells
CN113116933A (en) * 2021-04-26 2021-07-16 河北医科大学第四医院 Stem cell composition for preventing and treating diabetic foot and application thereof
CN114600872A (en) 2022-04-13 2022-06-10 西安北光医学生物技术有限公司 Method and system for anti-damage preservation of cells, tissues or organs
WO2024177862A1 (en) * 2023-02-20 2024-08-29 Intabio, Llc Methods for calibrating a mass spectrometry system

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020019046A1 (en) * 2000-01-11 2002-02-14 Carpenter Melissa K. Direct differentiation of human pluripotent stem cells and characterization of differentiated cells
WO2002018549A1 (en) * 2000-08-30 2002-03-07 Maria Biotech Co., Ltd. Human embryonic stem cells derived from frozen-thawed embryo
WO2004007696A2 (en) * 2002-07-11 2004-01-22 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
WO2004081172A2 (en) * 2003-03-12 2004-09-23 Reliance Life Sciences Pvt. Ltd. Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells
WO2005099758A2 (en) * 2004-04-17 2005-10-27 The Board Of Trustees The Leland Standford Junior University Injectable bioartificial tissue matrix

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744347A (en) 1987-01-16 1998-04-28 Ohio University Edison Biotechnology Institute Yolk sac stem cells and their uses
WO1990001541A1 (en) 1988-08-04 1990-02-22 Amrad Corporation Limited In vitro propagation of embryonic stem cells
US5256560A (en) 1988-10-07 1993-10-26 University Of Saskatchewan Primitive cell colony stimulating factors and lymphohematopoietic progenitor cells
US5411883A (en) 1989-12-26 1995-05-02 Somatix Therapy Corporation Proliferated neuron progenitor cell product and process
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5840580A (en) 1990-05-01 1998-11-24 Becton Dickinson And Company Phenotypic characterization of the hematopoietic stem cell
US5622853A (en) 1990-05-01 1997-04-22 Becton Dickinson And Company T lymphocyte precursor
DE69131393T2 (en) 1990-09-10 1999-11-04 Takeda Chemical Industries, Ltd. Human receptor for luteinizing hormone and chorionic gonadotropin
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US6410320B1 (en) 1992-03-02 2002-06-25 The University Of Michigan Method and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules
CA2109729A1 (en) 1992-03-23 1993-09-30 James G. Bender In vitro-derived human neutrophil precursor cells
AU4543193A (en) 1992-06-22 1994-01-24 Henry E. Young Scar inhibitory factor and use thereof
US5589376A (en) 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
US5690926A (en) 1992-10-08 1997-11-25 Vanderbilt University Pluripotential embryonic cells and methods of making same
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
JPH08506007A (en) 1992-11-16 1996-07-02 アプライド イミューン サイエンシーズ，インコーポレイテッド Pluripotent dormant stem cell population
DE4240635C2 (en) 1992-12-03 1997-07-10 Lothar Prof Dr Kanz Multiplication of hematopoietic progenitor cells ex vivo and compositions of hematopoietic growth factors
WO1995005843A1 (en) 1993-08-25 1995-03-02 Systemix, Inc. Method for producing a highly enriched population of hematopoietic stem cells
US5453457A (en) 1993-11-12 1995-09-26 Bayer Corporation Gamma-radiation-resistant polycarbonate composition
US5972627A (en) 1994-06-15 1999-10-26 Systemix, Inc. Method of purifying a population of cells enriched for dendritic and/or lymphoid progenitors and populations of cells obtained thereby
US5650317A (en) 1994-09-16 1997-07-22 Michigan State University Human breast epithelial cell type with stem cell and luminal epithelial cell characteristics
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5821108A (en) 1995-04-07 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker
US5876956A (en) 1995-05-15 1999-03-02 Johns Hopkins University School Of Medicine Methods for identification or purification of cells containing an enzymatic intracellular marker
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US6517872B1 (en) 1995-06-12 2003-02-11 Yeda Research And Development Co., Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells
US5753505A (en) 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
GB9514816D0 (en) 1995-07-19 1995-09-20 Ucli Ltd Substances and their medical use
US5858782A (en) 1995-11-13 1999-01-12 Regents Of The University Of Michigan Functional human hematopoietic cells
US5997871A (en) 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
US6969608B1 (en) 1996-08-26 2005-11-29 Mcgill University Pharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors
US6890724B2 (en) 1996-09-06 2005-05-10 California Institute Of Technology Methods and compositions for neural progenitor cells
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
CA2216439A1 (en) 1996-09-25 1998-03-25 Derek Van Der Kooy Pharmaceuticals containing retinal stem cells
JP2001508302A (en) 1997-01-10 2001-06-26 ライフ テクノロジーズ，インコーポレイテッド Embryonic stem cell serum replacement
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
US6331406B1 (en) 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US6734015B1 (en) 1997-07-04 2004-05-11 University Of Utah Research Foundation Isolation of lineage-restricted neuronal precursors
US6908763B1 (en) 1997-08-22 2005-06-21 The Board Of Trustees Of The Leland Stanford Junior University Mammalian common lymphoid progenitor cell
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6245757B1 (en) 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
WO1999020740A2 (en) 1997-10-23 1999-04-29 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
WO1999028486A1 (en) 1997-12-04 1999-06-10 Duke University Methods of isolating and using cd7+cd34-lin-hematopoietic cells
US6852533B1 (en) 1998-01-23 2005-02-08 Cornell Research Foundation, Inc. Purified populations of stem cells
AUPP244498A0 (en) * 1998-03-18 1998-04-09 Medvet Science Pty. Ltd. Keratinocyte stem cells
US6812027B2 (en) 1998-03-25 2004-11-02 Cornell Research Foundation, Inc. Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain
US6835567B1 (en) 1998-04-14 2004-12-28 Signal Pharmaceuticals, Inc. PNS cell lines and methods of use therefor
WO1999061587A1 (en) 1998-05-29 1999-12-02 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
US6129911A (en) 1998-07-10 2000-10-10 Rhode Island Hospital, A Lifespan Partner Liver stem cell
US6913925B1 (en) 1998-08-12 2005-07-05 Signal Pharmaceuticals Llc Human mesencephalon cell lines and methods of use therefor
DE19837438A1 (en) 1998-08-18 2000-02-24 Biotechnolog Forschung Gmbh Recombinant human cell for forming bone and cartilage cells from undifferentiated mesenchyme is capable of expressing a member of the T-box family of transcription factors
US6767737B1 (en) 1998-08-31 2004-07-27 New York University Stem cells bearing an FGF receptor on the cell surface
UA64826C2 (en) 1998-12-16 2004-03-15 Центр Ембріональних Тканин "Емселл" Method for treating patients using cellular suspensions of embryonic tissues
AU2794100A (en) 1999-02-24 2000-09-14 Novo Nordisk A/S Treatment of infertility
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
WO2000065068A1 (en) 1999-04-23 2000-11-02 Ceptyr, Inc. Dsp-10 dual-specificity map kinsase phosphatase
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
DE60036470T2 (en) 1999-06-29 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University, Palo Alto SUB-UNITS OF MYELOID PROGENITOR CELLS OF MAMMALS
US6761883B2 (en) 1999-06-29 2004-07-13 The Board Of Trustees Of The Leland Stanford Junior University Mammalian myeloid progenitor cell subsets
US6872389B1 (en) 1999-07-08 2005-03-29 Rhode Island Hospital Liver stem cell
US6043235A (en) 1999-07-21 2000-03-28 Research Triangle Institute 11β-aryl-17, 17-spirothiolane-substituted steroids
AU763021B2 (en) 1999-09-14 2003-07-10 Children's Medical Center Corporation Isolation of muscle-derived stem cells and uses therefor
AU7378600A (en) 1999-09-14 2001-04-17 Children's Medical Center Corporation Methods for treating muscular dystrophy
US20030082155A1 (en) * 1999-12-06 2003-05-01 Habener Joel F. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
JP2003517592A (en) 1999-12-13 2003-05-27 ザ スクリプス リサーチ インスティチュート Markers for identification and isolation of islet α and β precursors
US6416999B1 (en) 2000-04-07 2002-07-09 Raven Biotechnologies, Inc. Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
WO2001080865A2 (en) 2000-04-25 2001-11-01 Osiris Therapeutics, Inc. Joint repair using mesenchymal stem cells
NL1017973C2 (en) 2000-05-10 2002-11-08 Tristem Trading Cyprus Ltd Design.
US6936281B2 (en) 2001-03-21 2005-08-30 University Of South Florida Human mesenchymal progenitor cell
US20040071665A1 (en) 2000-09-05 2004-04-15 Yong-Fu Xiao Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
US6458588B1 (en) 2001-01-31 2002-10-01 The General Hospital Corporation Renal stem cells and uses thereof
CA2438501C (en) 2001-02-14 2014-09-16 Leo T. Furcht Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US6852532B2 (en) 2001-03-21 2005-02-08 University Of Utah Research Foundation Method of isolating human neuroepithelial precursor cells from human fetal tissue
CA2442177A1 (en) * 2001-03-29 2002-10-10 Ixion Biotechnology, Inc. Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
US20030017587A1 (en) 2001-07-18 2003-01-23 Rader William C. Embryonic stem cells, clinical applications and methods for expanding in vitro
DE10139783C1 (en) * 2001-08-14 2003-04-17 Transtissue Technologies Gmbh Cell compositions for the treatment of osteoarthritis, and methods for their production
WO2003040358A1 (en) * 2001-11-06 2003-05-15 Shanghai Second Medical University Somatic cell derived embryonic stem cells and its differentiated cells
US8021876B2 (en) 2001-11-15 2011-09-20 Children's Medical Center Corporation Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
US20030232430A1 (en) * 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
US7282222B2 (en) 2002-03-15 2007-10-16 The United States Of America As Represented By The Department Of Veterans Affairs Methods and compositions for directing cells to target organs
US20040009589A1 (en) 2002-03-26 2004-01-15 Shulamit Levenberg Endothelial cells derived from human embryonic stem cells
CN1307300C (en) 2002-07-25 2007-03-28 斯克里普斯研究学院 Hematopoietic stem cells and methods of treatment neogenesis vascular ophthalmopathy
NZ539713A (en) * 2002-10-11 2008-07-31 Novocell Inc Implantation of encapsulated biological materials for treating diseases
AR040783A1 (en) 2002-10-11 2005-04-20 Ligand Pharm Inc 5- (1 ', 1'-CYCLOAQUIL / ALQUENIL) METHYLIDEN-1,2-DIHYDRO-5-H-CHROMENE [3,4- F] CHIINOLINES AS SELECTING MODULATING COMPOUNDS OF PROGESTERONE RECEPTORS
TW200410968A (en) 2002-10-11 2004-07-01 Ligand Pharm Inc 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds
US20060252150A1 (en) * 2002-11-08 2006-11-09 Linzhao Cheng Human embryonic stem cell cultures, and compositions and methods for growing same
UA59678A (en) 2002-11-15 2003-09-15 Національний Медичний Університет Ім. О.О. Богомольця Method for treating rheumatoid arthritis
KR20060115351A (en) 2003-08-29 2006-11-08 위스콘신 얼럼나이 리서어치 화운데이션 In Vitro Differentiation of Neural Stem Cells, Motor Neurons and Dopamine Neurons of Primate Embryonic Stem Cell Origin
WO2005047524A2 (en) 2003-11-10 2005-05-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
WO2005052138A1 (en) 2003-11-19 2005-06-09 Wisconsin Alumni Research Foundation Cryopreservation of pluripotent stem cells
UA71388A (en) 2003-12-26 2004-11-15 Інститут Нейрохірургії Імені Академіка А. П. Ромоданова Академії Медичних Наук України A method for preparing enriched suspension of brainstem neural cells
US20050233446A1 (en) 2003-12-31 2005-10-20 Parsons Xuejun H Defined media for stem cell culture
WO2005080551A2 (en) 2004-02-12 2005-09-01 University Of Newcastle Upon Tyne Stem cells
CA2583473A1 (en) 2004-10-05 2007-04-04 University Of Georgia Research Foundation, Inc. Neuronal progenitors from feeder-free human embryonic stem cell culture
GEP20135796B (en) * 2006-03-07 2013-04-10 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020019046A1 (en) * 2000-01-11 2002-02-14 Carpenter Melissa K. Direct differentiation of human pluripotent stem cells and characterization of differentiated cells
WO2002018549A1 (en) * 2000-08-30 2002-03-07 Maria Biotech Co., Ltd. Human embryonic stem cells derived from frozen-thawed embryo
WO2004007696A2 (en) * 2002-07-11 2004-01-22 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
WO2004081172A2 (en) * 2003-03-12 2004-09-23 Reliance Life Sciences Pvt. Ltd. Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells
WO2005099758A2 (en) * 2004-04-17 2005-10-27 The Board Of Trustees The Leland Standford Junior University Injectable bioartificial tissue matrix

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
"The Stem Cell 'Miracles'", INTERNET CITATION, 23 May 2006 (2006-05-23), pages 1 - 5, XP002466331, Retrieved from the Internet <URL:http://sci.rutgers.edu/forum/showthread.php?t=57401> *
AMIT M ET AL: "Feeder Layer- and Serum-Free Culture of Human Embryonic Stem Cells", BIOLOGY OF REPRODUCTION 2004 UNITED STATES, vol. 70, no. 3, 2004, pages 837 - 845, XP002466324, ISSN: 0006-3363 *
DE SOUSA PAUL A ET AL: "The road to providing human embryo stem cells for therapeutic use: the UK experience", REPRODUCTION (CAMBRIDGE), vol. 132, no. 5, November 2006 (2006-11-01), pages 681 - 689, XP002466981, ISSN: 1470-1626 *
EZASHI T ET AL: "Low O2 tensions and the prevention of differentiation of hES cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 29 MAR 2005 UNITED STATES, vol. 102, no. 13, 29 March 2005 (2005-03-29), pages 4783 - 4788, XP002466326, ISSN: 0027-8424 *
G.S. MUDUR: "BIG WONDER CELLS MESS - Medical research guidelines in India leave doctors free to do what they wish", INTERNET CITATION, 20 November 2005 (2005-11-20), XP002466330, Retrieved from the Internet <URL:http://www.telegraphindia.com/1051120/asp/opinion/story_5496960.asp> *
GERAMI-NAINI BEHZAD ET AL: "Trophoblast differentiation in embryoid bodies derived from human embryonic stem cells.", ENDOCRINOLOGY APR 2004, vol. 145, no. 4, April 2004 (2004-04-01), pages 1517 - 1524, XP002466329, ISSN: 0013-7227 *
GERECHT-NIR S ET AL: "The promise of human embryonic stem cells", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL OBSTETRICS AND GYNAECOLOGY, BAILLIERE TINDALL, LONDON, GB, vol. 18, no. 6, December 2004 (2004-12-01), pages 843 - 852, XP004664903, ISSN: 1521-6934 *
GRUEN LORI ET AL: "Concise review: Scientific and ethical roadblocks to human embryonic stem cell therapy", STEM CELLS (MIAMISBURG), vol. 24, no. 10, October 2006 (2006-10-01), pages 2162 - 2169, XP002466982, ISSN: 1066-5099 *
HARPER J M ET AL: "Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 04 MAY 2004 UNITED STATES, vol. 101, no. 18, 4 May 2004 (2004-05-04), pages 7123 - 7128, XP002466977, ISSN: 0027-8424 *
HONG S H ET AL: "Expression of estrogen receptor-[alpha] and -[beta], glucocorticoid receptor, and progesterone receptor genes in human embryonic stem cells and embryoid bodies", MOLECULES AND CELLS 31 DEC 2004 GERMANY, vol. 18, no. 3, 31 December 2004 (2004-12-31), pages 320 - 325, XP002466327, ISSN: 1016-8478 *
KERR D A ET AL: "Human embryonic germ cell derivatives facilitate motor recovery of rats with diffuse motor neuron injury", JOURNAL OF NEUROSCIENCE 15 JUN 2003 UNITED STATES, vol. 23, no. 12, 15 June 2003 (2003-06-15), pages 5131 - 5140, XP002466978, ISSN: 0270-6474 *
KLIMANSKAYA I ET AL: "Human embryonic stem cells derived without feeder cells", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 365, no. 9471, 7 May 2005 (2005-05-07), pages 1636 - 1641, XP004882308, ISSN: 0140-6736 *
MANNELLO F ET AL: "Concise review: No breakthroughs for human mesenchymal and embryonic stem cell culture: Conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not go", STEM CELLS 2007 UNITED STATES, vol. 25, no. 7, 2007, pages 1603 - 1609, XP002466979, ISSN: 1066-5099 *
MCDONALD J W ET AL: "TRANSPLANTED EMBRYONIC STEM CELLS SURVIVE, DIFFERENTIATE AND PROMOTE RECOVERY IN INJURED RAT SPINAL CORD", NATURE MEDICINE, NATURE AMERICA, NEW YORK, US, vol. 5, no. 12, December 1999 (1999-12-01), pages 1410 - 1412, XP002933176, ISSN: 1078-8956 *
REUBINOFF B E ET AL: "Neural progenitors from human embryonic stem cells", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 19, no. 12, December 2001 (2001-12-01), pages 1134 - 1140, XP002971362, ISSN: 1087-0156 *
RICHARDS M ET AL: "An efficient and safe Xeno-Free Cryopreservation method for the storage of human embryonic stem cells", STEM CELLS, ALPHAMED PRESS, DAYTON, OH, US, vol. 22, no. 5, 2004, pages 779 - 789, XP002376917, ISSN: 1066-5099 *
SCHULDINER MAYA ET AL: "Effects of eight growth factors on the differentiation of cells derived from human embryonic stem cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 97, no. 21, 10 October 2000 (2000-10-10), pages 11307 - 11312, XP002184277, ISSN: 0027-8424 *
SHI Q J ET AL: "Novel role of human chorionic gonadotropin in differentiation of human cytotrophoblasts", ENDOCRINOLOGY 1993 UNITED STATES, vol. 132, no. 3, 1993, pages 1387 - 1395, XP002466328, ISSN: 0013-7227 *
SKOTTMAN HELI ET AL: "Culture conditions for human embryonic stem cells", REPRODUCTION (CAMBRIDGE), vol. 132, no. 5, November 2006 (2006-11-01), pages 691 - 698, XP002466980, ISSN: 1470-1626 *
STOJKOVIC P ET AL: "HUMAN-SERUM MATRIX SUPPORTS UNDIFFERENTIATED GROWTH OF HUMAN EMBRYONIC STEM CELLS", STEM CELLS, ALPHAMED PRESS, DAYTON, OH, US, vol. 23, no. 7, August 2005 (2005-08-01), pages 895 - 902, XP009065121, ISSN: 1066-5099 *
WANG W-H ET AL: "Human embryonic stem cell lines are contaminated: What should we do?", HUMAN REPRODUCTION 2005 UNITED KINGDOM, vol. 20, no. 11, 2005, pages 2987 - 2989, XP002466325, ISSN: 0268-1161 1460-2350 *
ZHANG S-C ET AL: "In vitro differentiation of transplantable neural precursors from human embryonic stem cells", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 19, no. 12, December 2001 (2001-12-01), pages 1129 - 1133, XP002268706, ISSN: 1087-0156 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102119031B (en) * 2008-06-11 2014-09-10 弗雷森纽斯医疗护理德国有限责任公司 Conditioned media for hepatic progenitor cells

Also Published As

Publication number Publication date
DK1993575T3 (en) 2019-10-14
JP5649786B2 (en) 2015-01-07
MX347303B (en) 2017-04-21
EP2422798A3 (en) 2013-03-06
US8592208B2 (en) 2013-11-26
EP1993575B1 (en) 2019-07-03
PH12014501028A1 (en) 2016-02-22
EP2422801A3 (en) 2013-03-06
AU2007257594A1 (en) 2007-12-13
EP2422801A2 (en) 2012-02-29
AU2007257594B2 (en) 2012-11-01
EA027648B9 (en) 2018-01-31
CN103893211A (en) 2014-07-02
EA027648B1 (en) 2017-08-31
US20140051164A1 (en) 2014-02-20
US9134299B2 (en) 2015-09-15
NZ594639A (en) 2013-04-26
US10545135B2 (en) 2020-01-28
EP2422800A3 (en) 2013-03-06
KR101505382B1 (en) 2015-03-23
US20190369088A1 (en) 2019-12-05
EP2422796A2 (en) 2012-02-29
EP2422795A3 (en) 2013-03-13
CN101420964A (en) 2009-04-29
IL193702A (en) 2015-02-26
IL193702A0 (en) 2011-08-01
NZ571127A (en) 2012-01-12
NO20084181L (en) 2008-11-26
EP1993575A2 (en) 2008-11-26
CU20080161A7 (en) 2012-11-15
US8900861B2 (en) 2014-12-02
CA2644922C (en) 2019-07-23
EP2422794A2 (en) 2012-02-29
US9488643B2 (en) 2016-11-08
EA200801943A1 (en) 2009-04-28
US20130122486A1 (en) 2013-05-16
MY154677A (en) 2015-07-15
WO2007141657B1 (en) 2008-07-31
EP2422802A2 (en) 2012-02-29
US20140057350A1 (en) 2014-02-27
EP2422803A2 (en) 2012-02-29
US20140057250A1 (en) 2014-02-27
EP2422798A2 (en) 2012-02-29
MX2008011279A (en) 2008-11-25
JP2014159455A (en) 2014-09-04
BRPI0708576A2 (en) 2011-05-31
KR101505202B1 (en) 2015-03-27
US20140051110A1 (en) 2014-02-20
KR20080106332A (en) 2008-12-04
MA30323B1 (en) 2009-04-01
GEP20135796B (en) 2013-04-10
EP2422799A3 (en) 2013-03-06
EP2422803A3 (en) 2013-03-13
WO2007141657A2 (en) 2007-12-13
EP2422794A3 (en) 2013-03-13
US20140050706A1 (en) 2014-02-20
EP2422802A3 (en) 2013-03-06
US9482660B2 (en) 2016-11-01
JP2009528834A (en) 2009-08-13
EP2422797A3 (en) 2013-03-20
CA2644922A1 (en) 2007-12-13
ECSP088799A (en) 2008-12-30
EP2422797A2 (en) 2012-02-29
EP2422796A3 (en) 2013-03-13
US20130122588A1 (en) 2013-05-16
AP2008004623A0 (en) 2008-10-31
AP2949A (en) 2014-07-31
CR10345A (en) 2009-03-30
KR20140135263A (en) 2014-11-25
US9383349B2 (en) 2016-07-05
EP2422795A2 (en) 2012-02-29
US20090123433A1 (en) 2009-05-14
EP2422799A2 (en) 2012-02-29
EP2422800A2 (en) 2012-02-29
US9804151B2 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
PH12014501028A1 (en) Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
WO2006044204A3 (en) Neuronal progenitors from feeder-free human embryonic stem cell culture
EP3275999B1 (en) Method for inducing pluripotent stem cells and pluripotent stem cells prepared by said method
WO2011063005A3 (en) Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
KR101757827B1 (en) Hyaluronidase Inhibitor Including Extrat of Styrax japonica and the Phamaceutical Composition Comprising the Same
JP2016202098A (en) Stem cell undifferentiated state maintenance agent and growth promoter using mannentake extract
KR102122614B1 (en) Composition comprising Tetrathelmis tetrathele extract for improving condition of hair and preventing hair loss
US20230045902A1 (en) Composition for reinforcing function of stem cell
KR101902425B1 (en) Agent for improving regeneration comprising Gardenia jasminodes extracts
UA99813C2 (en) Composition comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
KR20130079281A (en) Pharmaceutical composition comprising extract or fraction of lagerstroemia ovalifolia for prevention or treatment of inflammatory diseases or asthma
JP6583679B2 (en) Stem cell undifferentiated state maintenance agent and growth promoter using yeast extract
JP6571494B2 (en) Stem cell undifferentiated state maintenance agent and growth promoter using Ainu Wakame
WO2014203883A1 (en) Hyaluronic acid production promoter
WO2006010084A3 (en) A system for delivering therapeutic agents into living cells and cell nuclei
WO2007089950A3 (en) Preparations of growth hormone
Bukovsky et al. Ovarian germ cells
JP6411778B2 (en) Stem cell undifferentiated state maintenance agent and growth promoter
CU20130075A7 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES HUMAN MOTHER CELLS AND THEIR DERIVATIVES AND PREPARATION METHODS
KR20180046021A (en) Composition including neoagarooligosaccharide for preventing, improving or treating inflammatory disease
KR101835180B1 (en) Recombinant BTG2 protein and production method thereof
WO2005056780A3 (en) Cell culture with nm23, cell culture media comprising nm23 and therapeutic use of cells cultured in the presence of nm23.
KR20150146097A (en) Hyaluronidase Inhibitor Including Extrat of Styrax japonica and the Phamaceutical Composition Comprising the Same
Ju et al. Effects of physiological active substance extracted from silkworm fece
Jayawardana et al. Protease inhibitory activity of some medicinal plants in Sri Lanka

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 193702

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12008501979

Country of ref document: PH

Ref document number: MX/a/2008/011279

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2644922

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008557853

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2008091493

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 2007257594

Country of ref document: AU

Ref document number: 12224839

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 571127

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 3853/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: DZP2008000557

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2007789615

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007257594

Country of ref document: AU

Date of ref document: 20070306

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 08105992

Country of ref document: CO

Ref document number: 1020087024426

Country of ref document: KR

Ref document number: CR2008-010345

Country of ref document: CR

WWR Wipo information: refused in national office

Ref document number: CR2008-010345

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 10928

Country of ref document: GE

Kind code of ref document: P

WWE Wipo information: entry into national phase

Ref document number: A200811727

Country of ref document: UA

Ref document number: 200801943

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 200780013128.X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: CR2008-010345

Country of ref document: CR

ENP Entry into the national phase

Ref document number: PI0708576

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080905

WWE Wipo information: entry into national phase

Ref document number: IDP00201500212

Country of ref document: ID